Deferasirox effect on leukemia cell line: dose response
Summary:
Analysis of leukemia K562 cells treated with 10 or 50 uM deferasirox. Deferasirox is an iron chelator taken orally to treat iron toxicity. Iron depletion by deferasirox inhibits cancer cell proliferation in vitro. Results provide insight into the molecular basis of this anti-proliferative effect.
GPL570:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
Citation:
Ohyashiki JH, Kobayashi C, Hamamura R, Okabe S et al. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer Sci 2009 May;100(5):970-7. PMID: 19298223
